BioStock: PHI aims for US listing

July 11, 2024
Language flag

Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.

Read the full interview with Patrik Eschricht on biostock.se.

We are very happy about the possibility of dual-listing on the OTCQB, which would be another significant step in PHI’s growth journey as a global company. This dual listing would make it more accessible for international investors to invest in PHI, positively increasing liquidity, boosting shareholder value, and supporting our ongoing growth.

Further reading

PHI-accelerates-growth-with-record-order-biostock

BioStock: PHI accelerates growth with record order

PHI recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.
Biostock PHI CEO comments on the approved US listing

BioStock: PHI’s CEO comments on the approved US listing

PHI has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
2024-08-15-Proactive-CEO-interview-OTCQBPHIXF

OTC Market Center in New York welcomes PHI

Our very own ‘big apple’ news — PHI’s shares (OTCQB:PHIXF) are now also trading on the US-OTCQB Market! Go and see some snapshots and our CEO Patrik speaking on this exciting new chapter.
Interview-John-More-website

Interview with John Moore

Meet John Moore, the proposed new board member for PHI. John’s extensive experience and visionary mindset make him an invaluable addition to our team. Let’s dive into his journey and what made him interested in PHI.
123456…10

Latest News

A red pin on a blue map.

Phase Holographic: Proposal to amend the Altium Distribution Agreement

Phase Holographic Imaging PHI AB (“PHI” or the “Company”) announces that the Board of Directors has decided to call for an Extraordinary General Meeting to approve a proposed amendment of the distribution agreement with Altium SA (“Altium”), the Company’s global distributor and main shareholder.
A magnifying glass on a paper with blue charts.

Phase Holographic: Sales summary and profit warning for the fiscal year 2024/2025

Phase Holographic Imaging PHI AB (“PHI” or the “Company”) today provides an update on the Company’s sales for the fiscal year 2024/2025. Based on the most recent developments and actual order volumes, total sales for the fiscal year are now expected to amount to approximately EUR 1.5 million, compared to the estimate of EUR 2 million, communicated through a sales outlook in December 2024.
Phase Holographic Imaging logotype

Phase Holographic: PHI has appointed Patrik Eschricht as new CEO

Phase Holographic Imaging PHI AB today announces that Patrik Eschricht, former CEO of PHI, will come back as CEO of the Company, effective immediately. He returns to the role he held during 2023 and most of 2024.
See All News